Learn More
Two-year experiments were performed to evaluate the neurotrophic effect of hypoxia-inducible factors (vascular endothelial growth factor and angiogenin) expressed in recombinant human adenoviruses in amyotrophic lateral sclerosis. Randomized placebo-controlled trial demonstrated safety and good tolerability of the recombinant antiviral drugs. The life span(More)
Multiple sclerosis (MS) is an immune-mediated disorder associated with inflammation, demyelination and axonal damage. In search of potential biomarkers of spinal cord lesions in MS related to nitric oxide metabolites, we measured total nitrite and nitrate levels, and protein-bound nitrotyrosine and S-nitrosothiol concentrations in the serum of MS patients(More)
Multiple sclerosis is a chronic demyelinating disorder of the central nervous system. There are many cases of multiple sclerosis - like syndrome and demyelinating disorders in systemic lupus erythematosus, Sjogren disease, Behcet disease and other autoimmune conditions. Coexistence of ankylosing spondylitis and multiple sclerosis usually is rare but in this(More)
Amyotrophic lateral sclerosis (ALS) is a continuously progressing neurodegenerative disease that is characterized by selective damage to motoneurons in the neocortex, brainstem, and spinal cord. The general opinion is that sporadic ALS is a multifactor and multigene disease. Realization of its genetic predisposition is determined by environmental factors.(More)
The “Sovet” post-marketing observational program was started in 2011. A total of 69 patients with the remitting form of multiple sclerosis (MS) treated with the second-generation DMD natalizumab (NZ) were studied. NZ infusions were given over 1 h every four weeks for 12 months. Treatment produced significant reductions in the frequency of exacerbations of(More)
Motor neuron disease (MND), or amyotrophic lateral sclerosis, is a fatal neurodegenerative disorder characterized by a progressive loss of motor neurons in the spinal cord and the brain. Several angiogenic and neurogenic growth factors, such as the vascular endothelial growth factor (VEGF), angiogenin (ANG), insulin-like growth factor (IGF) and others, have(More)
The post marketing observational program "Sovet" has been launched in 2011. Sixty-nine patients with relapsing-remitting multiple sclerosis (MS) treated with natalizumab (NZ), a second generation DMD, have been examined. NZ infusions were carried out during 1h every 4 weeks for 12 months. After treatment, there were a significant reduction in the frequency(More)
  • 1